ArticleClinical cancer research : an official journal of the American Association for Cancer Research2019
A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.
Abstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- MITF-Driven melanoma plasticity as a core mechanism of therapy resistance: integrating microenvironmental signaling, mechanotransduction, and metabolic reprogramming.Cell cycle (Georgetown, Tex.) · 2026Review
- The multifaceted role of 3-methyladenine in cancer therapy.Journal of physiology and biochemistry · 2026Review
- Metabolism, autophagy, and cell death: The triangular axis in tumor survival and therapeutic resistance.Redox biology · 2026Review
- Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).International journal of oncology · 2026Review
- Personalized targeting of BCL2 family proteins overcomes acquired resistance to BRAF-MEK inhibitors in preclinical melanoma.Nature communications · 2026Article
- Decoding the metabolic cipher of dormant cancer cells: molecular mechanisms and therapeutic potentials.Cell communication and signaling : CCS · 2026Review
- Loss of ten-eleven translocation 2 (TET2) facilitates aggressive behaviour in cutaneous melanoma by inducing peroxisome proliferator-activated receptor-γ coactivator 1α expression and oxidative phosphorylation.The British journal of dermatology · 2026Article
- TET2 downregulation limits oxidative stress-induced cytotoxicity of high dose ascorbate in dabrafenib-resistant melanoma cells.Cancer drug resistance (Alhambra, Calif.) · 2026Article
- mTOR signaling networks: mechanistic insights and translational frontiers in disease therapeutics.Signal transduction and targeted therapy · 2025Review
- A TROP2-targeting ADC synergizes with oxidative phosphorylation inhibitor to enhance apoptosis in ESCC by suppressing the PI3K-AKT-mTOR signaling pathway.Cell death & disease · 2025Article
- Genetic Insight into Expression-Defined Melanoma Subtypes and Network Mechanisms: An in Silico Study.Genes · 2025Article
- Mitochondrial bioenergetics and networks in melanoma: an update.Apoptosis : an international journal on programmed cell death · 2025Review
- Metabolic adaptations of brain metastasis.Nature reviews. Cancer · 2025Review
- Metabolic reprogramming in melanoma therapy.Cell death discovery · 2025Review
- Exploiting mitochondrial dysfunction to overcome BRAF inhibitor resistance in advanced melanoma: the role of disulfiram as a copper ionophore.Cell death & disease · 2025Article
- G-protein coupled receptors in metabolic reprogramming and cancer.Pharmacology & therapeutics · 2025Review
- Tumor Microenvironment in Melanoma Brain Metastasis: A New Potential Target?International journal of molecular sciences · 2025Review
- Integrated analysis of molecular and clinical features associated with overall survival in melanoma patients with brain metastasis.Acta neuropathologica communications · 2025Article
- Lysosomal-Mitochondrial Interaction Promotes Tumor Growth in Squamous Cell Carcinoma of the Head and Neck.Molecular cancer research : MCR · 2025Article
- DNA replication stress underpins the vulnerability to oxidative phosphorylation inhibition in colorectal cancer.Cell death & disease · 2025Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Y N Vashisht GopalDepartment of Melanoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas. vynanda@mdanderson.org.
Seth GammonDepartment of Cancer Systems Imaging, University of Texas M.D. Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8647-0975
Rishika PrasadDepartment of Melanoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Barbara KnightonDepartment of Melanoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Federica PisaneschiDepartment of Cancer Systems Imaging, University of Texas M.D. Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-1989-4417
Jason RoszikDepartment of Melanoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4561-6170
Ningping FengCenter for Co-Clinical Trials, University of Texas M.D. Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1917-9648
Sarah JohnsonCenter for Co-Clinical Trials, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Snigdha PramanikDepartment of Melanoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Jessica SudderthChildren's Medical Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas.
Dawen SuiDepartment of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Courtney HudgensDepartment of Translational Molecular Pathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8312-7485
Grant M FischerDepartment of Melanoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Wanleng DengDepartment of Melanoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Alexandre ReubenDepartment of Thoracic H&N Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4510-0382
Weiyi PengDepartment of Biology and Biochemistry, University of Houston, Houston, Texas.ORCID 0000-0002-7785-6240
Jian WangDepartment of Biostatistics, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Jennifer L McQuadeDepartment of Melanoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2393-2172
Michael T TetzlaffDepartment of Translational Molecular Pathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0977-0912
Maria E Di FrancescoInstitute for Applied Cancer Science, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Joe MarszalekCenter for Co-Clinical Trials, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
David Piwnica-WormsDepartment of Cancer Systems Imaging, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Ralph J DeBerardinisChildren's Medical Research Institute, University of Texas Southwestern Medical Center, Dallas, Texas.
Michael A DaviesDepartment of Melanoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0977-0912
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MWU-MDACC Inter-Institutional Molecular Imaging CenterP50CA094056 · NCI · WASHINGTON UNIVERSITY · PI KOPAN, RAPHAEL · 2002 to 2016
$26.3MCenter for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4MTRAINING FOR ACADEMIC ONCOLOGY/HEMATOLOGYT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Michael Davies, Courtney DiNardo · 1994 to 2026
$9.8MCenter for Clinical and Translational Sciences (CCTS)TL1TR000369 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$1.9M[18F]FAZA PET/CT for Monitoring Target Engagement of a Novel Complex I InhibitorR01CA231506 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PIWNICA-WORMS, DAVID · 2019 to 2020
$610kNCATS NIH HHS TL1 TR000369NCATS NIH HHS UL1 TR000371NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA094056NCI NIH HHS R01 CA231506NCI NIH HHS T32 CA009666
Abstract
purposeThe purpose of this study is to determine if inhibition of mitochondrial oxidative phosphorylation (OxPhos) is an effective strategy against MAPK pathway inhibitor (MAPKi)-resistant BRAF-mutant melanomas.
resultsOPi potently inhibited OxPhos and the
conclusionsTargeting OxPhos with OPi has significant antitumor activity in MAPKi-resistant, BRAF-mutant melanomas, and merits further clinical investigation as a potential new strategy to overcome intrinsic and acquired resistance to MAPKi in patients.
Indexed as
AMP-Activated Protein Kinase KinasesAnimalsCell Line, TumorDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHeterograftsHumansMAP Kinase Signaling SystemMelanomaMiceMitochondriaOxadiazolesOxidative PhosphorylationPiperidinesPositron-Emission TomographyProtein Kinase InhibitorsAMP-Activated Protein Kinase KinasesBRAF protein, humanIACS-010759MTOR protein, humanOxadiazolesPiperidinesProtein Kinase InhibitorsProtein KinasesProto-Oncogene Proteins B-rafTOR Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.